Amgen
Amgen drug pair become first Humira biosimilars to win EU approval
January 30, 2017Sales and Marketing AbbVie, Amgen, Amgevita, Humira, Solymbic, rheumatoid arthritis
Good news for Amgen as its two biosimilar versions of AbbVie’s blockbuster rheumatoid arthritis (RA) drug Humira (adalimumab) have been …
Amgen and Immatics enter $1bn immuno-oncology partnership
January 9, 2017Research and Development, Sales and Marketing Amgen, immatics, immunotherapy
Amgen has announced it is to join forces with cancer immunotherapy biotech Immatics Biotechnologies in a partnership potentially worth over …
Amgen’s patent win upheld against Sanofi-Regeneron
January 4, 2017Medical Communications, Research and Development Amgen, Regeneron, Sanofi, patent
In March 2016, Amgen won two major patent cases against Sanofi and Regeneron over their drug, Praleunt, after it was …
Humira biosimilar proves efficacy in Phase 3 trial
November 30, 2016Research and Development AbbVie, Amgen, FDA, Humira, M923, Momenta
US-based biotechnology firm Momenta Pharmaceuticals has announced that its biosimilar version of Abbvie’s autoimmune drug Humira (adalimumab) – currently the …
Amgen boosted in race to market for migraine drug
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III
Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …
NICE turns down Amgen’s multiple myeloma drug
November 9, 2016Research and Development, Sales and Marketing Amgen, Kyprolis, NICE
Amgen has seen its drug Kyprolis (carfilzomib) rejected by NICE for its routine use in the treatment of multiple myeloma …
FDA approves first therapy for paediatric psoriasis treatment
November 7, 2016Sales and Marketing Amgen, Enbrel, paediatric, psoriasis
Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. …
EMA opens clinical trial data to public
October 25, 2016Manufacturing and Production Amgen, AstraZeneca, EMA, EU, Kyprolis, clinical reports, clinical trials
The European Medicine Agency has begun to release to the public data on clinical trial via their own website. The …
Amgen’s Kyprolis disappoints in Phase III trial
September 27, 2016Manufacturing and Production, Research and Development Amgen, Kyprolis, phase III
Amgen was relying on the results of the trial to justify its $10.4 billion purchase of Onyx Pharmaceuticals, acquiring Kyprolis …
FDA gives the green light to the first Humira biosimilar
September 26, 2016Sales and Marketing AbbVie, Amgen, Amjevita, FDA, Humira
Amgen’s Amjevita has been given the go ahead for all eligible indications of its reference product, including moderate-to-severe rheumatoid arthritis, …
Positive Phase III results for Amgen’s Repatha for coronary artery disease
September 21, 2016Research and Development Amgen, Phase III trial, Repatha
Amgen has announced that its monoclonal antibody Repatha (evolocumab) achieved positive Phase III results for the treatment of coronary artery …
Amgen’s leukaemia treatment given FDA thumbs up for use in paediatric patients
September 2, 2016Medical Communications, Sales and Marketing Amgen, FDA, blincyto, leukaemia
Amgen has announced that the FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) in the treatment of …
Amgen’s Prolia achieves positive top-line Phase III results after 12 months
August 30, 2016Manufacturing and Production, Research and Development Amgen, Prolia, denosumab, phase III
Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …
FDA says no to Amgen’s Parsabiv
August 25, 2016Research and Development, Sales and Marketing Amgen, FDA, par
Amgen has announced that the US Food and Drug Administration (FDA) has issued a complete response letter rejecting Parsabiv (etelcalcetide) …
Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds
August 17, 2016Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent
A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
